Next Generation Mobile EEC
Inflamax’s Next Generation Mobile EEC Technology1 Allows the Study of Allergic Conjunctivitis and Dry Eye Syndrome in a Multi-center Approach suitable for Pivotal Phase III Trials.
1Patent pending technologies.
Inflamax’s Mobile EEC is a proprietary system built on the same principles and to the same exacting standards as our static EECs. They may be strategically positioned globally to facilitate cost-effective and timely recruitment of your multi-center trials. A hybrid design clinical trial utilizing our Mobile EECs can combine the best of traditional field trials and EEC models to control environmental provocateurs.
The advantages of using our validated Mobile EECs are:
- They provide consistent environmental controls in any global region reducing single center bias.
- Improved patient screening to ensure that only adequately symptomatic patients are enrolled.
- Gain access to the patient population and investigators required to meet jurisdictional drug or device approval requirements.